<DOC>
	<DOCNO>NCT00084734</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , capecitabine , cisplatin , work different way stop tumor cell divide stop grow die . Giving one chemotherapy drug may kill tumor cell . PURPOSE : This phase I trial study side effect best dose docetaxel , capecitabine , cisplatin treat patient metastatic unresectable solid tumor .</brief_summary>
	<brief_title>Docetaxel , Capecitabine , Cisplatin Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose docetaxel , cisplatin , capecitabine patient advance solid tumor . - Determine dose-limiting toxicity recommend phase II dose regimen patient . Secondary - Determine non-dose-limiting toxic effect associate regimen patient . - Determine pharmacokinetics regimen patient . - Determine clinical activity regimen patient . OUTLINE : This dose-escalation study . Patients receive docetaxel IV 30 minute cisplatin IV 30 minute day 1 8 oral capecitabine twice daily day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos docetaxel , cisplatin , capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient receive treatment MTD . PROJECTED ACCRUAL : A minimum 21 patient accrue study within 1.5 year .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor standard curative palliative measure exist longer effective Metastatic unresectable disease No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy More 12 week Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL Hepatic AST ALT ≤ 2.0 time upper limit normal ( ULN ) AND alkaline phosphatase [ AP ] &lt; ULN OR AP ≤ 4 time ULN AND AST ALT &lt; ULN Bilirubin normal Renal Creatinine ≤ 1.5 mg/dL OR Creatinine clearance ≥ 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able ingest oral medication No allergy attribute study drug , compound similar chemical biological composition , drug formulate polysorbate 80 , agent use study No inner ear auditory toxicity ≥ grade 2 No peripheral neuropathy ≥ grade 2 No immunodeficiency No active ongoing infection No psychiatric illness social situation would preclude study compliance No concurrent uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent growth factor ( sargramostim [ GMCSF ] filgrastim [ GCSF ] ) Chemotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy recover Surgery Not specify Other No concurrent investigational agent unless approve principal investigator medical monitor No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>